Metlife Inc (NYSE:MET) Shares Bought by Cullinan Associates Inc.

Share on StockTwits

Cullinan Associates Inc. boosted its stake in shares of Metlife Inc (NYSE:MET) by 7.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 113,501 shares of the financial services provider’s stock after purchasing an additional 7,524 shares during the period. Cullinan Associates Inc.’s holdings in Metlife were worth $5,785,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. United Capital Financial Advisers LLC lifted its stake in shares of Metlife by 11.2% during the second quarter. United Capital Financial Advisers LLC now owns 36,421 shares of the financial services provider’s stock worth $1,809,000 after buying an additional 3,658 shares during the period. Evercore Wealth Management LLC raised its stake in Metlife by 17.3% in the 2nd quarter. Evercore Wealth Management LLC now owns 6,137 shares of the financial services provider’s stock worth $304,000 after acquiring an additional 906 shares during the last quarter. Asset Management One Co. Ltd. raised its stake in Metlife by 17.7% in the 2nd quarter. Asset Management One Co. Ltd. now owns 538,755 shares of the financial services provider’s stock worth $26,760,000 after acquiring an additional 80,916 shares during the last quarter. Rampart Investment Management Company LLC raised its stake in Metlife by 390.8% in the 2nd quarter. Rampart Investment Management Company LLC now owns 43,914 shares of the financial services provider’s stock worth $2,181,000 after acquiring an additional 34,967 shares during the last quarter. Finally, National Pension Service lifted its position in Metlife by 7.0% during the 2nd quarter. National Pension Service now owns 1,056,680 shares of the financial services provider’s stock worth $52,485,000 after acquiring an additional 68,862 shares during the period. 74.46% of the stock is currently owned by institutional investors.

NYSE MET traded down $0.34 on Wednesday, reaching $51.85. 4,299,992 shares of the company’s stock traded hands, compared to its average volume of 5,870,965. The firm has a market cap of $47.70 billion, a price-to-earnings ratio of 9.62, a P/E/G ratio of 1.01 and a beta of 1.13. The stock has a 50 day moving average price of $50.67 and a 200-day moving average price of $48.32. Metlife Inc has a fifty-two week low of $41.41 and a fifty-two week high of $52.76. The company has a debt-to-equity ratio of 0.21, a quick ratio of 0.15 and a current ratio of 0.15.

Metlife (NYSE:MET) last posted its quarterly earnings results on Wednesday, October 30th. The financial services provider reported $1.27 EPS for the quarter, missing the consensus estimate of $1.40 by ($0.13). The business had revenue of $16.92 billion during the quarter, compared to analysts’ expectations of $16.37 billion. Metlife had a net margin of 10.82% and a return on equity of 8.82%. Metlife’s revenue for the quarter was up 3.2% compared to the same quarter last year. During the same period in the previous year, the company posted $1.38 earnings per share. As a group, equities research analysts anticipate that Metlife Inc will post 5.53 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 13th. Stockholders of record on Tuesday, February 4th will be issued a $0.44 dividend. The ex-dividend date of this dividend is Monday, February 3rd. This represents a $1.76 annualized dividend and a dividend yield of 3.39%. Metlife’s dividend payout ratio (DPR) is presently 32.65%.

MET has been the topic of several research analyst reports. B. Riley reiterated a “neutral” rating on shares of Metlife in a research note on Tuesday, October 15th. Zacks Investment Research upgraded Metlife from a “sell” rating to a “hold” rating and set a $52.00 price objective for the company in a research note on Monday, December 9th. UBS Group lifted their target price on Metlife from $46.00 to $47.00 and gave the stock a “neutral” rating in a report on Thursday, October 10th. ValuEngine upgraded Metlife from a “strong sell” rating to a “sell” rating in a research report on Saturday, December 21st. Finally, Morgan Stanley upgraded Metlife from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $55.00 to $60.00 in a research report on Tuesday, January 7th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and five have assigned a buy rating to the company. Metlife presently has an average rating of “Hold” and an average price target of $50.34.

Metlife Company Profile

MetLife, Inc engages in the insurance, annuities, employee benefits, and asset management businesses. It operates through five segments: U.S.; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short- and long-term disability, individual disability, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and stable value products, including general and separate account guaranteed interest contracts, and private floating rate funding agreements.

Featured Article: How interest rates affect municipal bond prices

Want to see what other hedge funds are holding MET? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Metlife Inc (NYSE:MET).

Institutional Ownership by Quarter for Metlife (NYSE:MET)

Receive News & Ratings for Metlife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metlife and related companies with MarketBeat.com's FREE daily email newsletter.